Dual-Targeting CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma

Clinical trial NCT07480928 · RECRUITING

Trial details

NCT number: NCT07480928
Sponsor: Beijing Biotech
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Pancreatic Ductal Adenocarcinoma (PDAC)Unresectable Locally Advanced or Metastatic Disease

Start date: 2026-02-02
Primary completion: 2027-02-14
Enrollment: 42

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.